Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Approval  ·  Weekly Digest - 20 June to 26 June 2026

Biokin Pharma secures first China approval for Iza-bren in Nasopharyngeal carcinoma

By Sandhya Ramalingam  Published On 26 June 2026

Weekly Digest - June 2026

Weekly Digest - June 2026

22 June 2026: SystImmune secures first China approval for Iza-bren in Nasopharyngeal carcinoma

  • Biokin Pharma has received NMPA approval for Iza-bren for the treatment of recurrent or metastatic nasopharyngeal carcinoma following prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy, marking the world’s first approval of an EGFR×HER3 bispecific antibody-drug conjugate and a major milestone for patients with limited treatment options
  • The approval was supported by results from the pivotal phase 3 BL-B01D1-303 trial, where Iza-bren achieved a confirmed objective response rate of 54.6% compared with 27.0% for chemotherapy, while also demonstrating a median duration of response of 8.5 months versus 4.8 months and a median progression-free survival of 8.38 months versus 4.34 months, significantly outperforming physician’s choice chemotherapy
  • The approval provides a new treatment option for recurrent or metastatic NPC patients who have progressed after standard chemotherapy and immunotherapy, a population with poor prognosis and a five-year overall survival rate typically below 10%, highlighting the substantial unmet need in this setting
  • Iza-bren is a first-in-class EGFR×HER3 bispecific ADC that simultaneously blocks EGFR and HER3 signaling pathways while delivering a proprietary brengitecan-based topoisomerase I inhibitor payload, combining dual-target inhibition with targeted cytotoxic activity against tumor cells
  • Strategically, the approval represents the first regulatory approval of any bispecific ADC globally, validating SystImmune’s proprietary ADC platform and establishing a strong foundation for broader development of Iza-bren across multiple tumor types, while strengthening the company’s position in the increasingly competitive next-generation ADC landscape

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home

Funding

Related Articles


Deals  ·  Weekly Digest 11 Jan to 17 Jan 2025
Daiichi Sankyo acquires Intellectual Property Rights for anti-TAMUC1 antibody in DS-3939 from Glycotope GmbH
Regulatory  ·  Weekly Digest - 24 January to 30 January 2026
Henlius receives an IND approval for Its PD-L1-targeting ADC HLX43 in combination with anti-PD-1 mAb Serplulimab and novel anti-EGFR mAb HLX07
Clinical  ·  Weekly Digest 03 May to 09 May 2025
ENHERTU (Trastuzumab deruxtecan) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase 3 trial

Leave A Reply Cancel reply

Your email address will not be published. Required fields are marked *

*

*

U.S. FDA approves Trodelvy for first-line treatment of metastatic TNBC
Previous Article
Weekly News 27 June to 03 July 2026
Next Article

Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id